Management Team
Junyuan Jerry Wang, Ph.D.
CEO & Co-Founder
Dr. Junyuan (Jerry) Wang is Chief Executive Officer & Co-Founder at AnHeart Therapeutics. He has more than 20 years of leadership experience in global clinical development and medical research, having previously worked at Merck Serono, BMS, Wyeth/Pfizer, The Medicines Company, and Merck & Co. He has broad drug development experience across multiple therapeutic areas including oncology, cardiovascular, neuroscience, and immunology. He has made key contributions to successful NDA of Bosulif and Eliquis, and the latter became multi-billion blockbuster drug. He has extensive experience with global health authorities including FDA, EMA, PMDA and NMPA. He also served in leadership roles for professional societies and on the programming committee of leading scientific conferences. Dr. Wang earned his B.S. from the University of Science and Technology of China and Ph.D. in Statistics from Iowa State of University.
Bing Yan, M.D., MBA
Co-Founder & President, AnHeart China
Dr. Bing Yan is President, AnHeart China and Co-Founder at AnHeart Therapeutics. He was trained as a medical doctor and has more than 20 years of pharmaceutical industry experience in novel drug and vaccine development, regulatory interactions, and post-approval activities. Prior to joining AnHeart, Dr. Yan was the Global Vice-President and Head of Asia Pacific Clinical Research at Pfizer. He has deep experience across multiple therapeutic areas including neuroscience, vaccines, anti-infectives, transplant, oncology, men’s/women’s health and metabolic disorders. He played a significant leadership role in bringing Prevnar13, Xalkori, Lyrica, Enbrel, Pristiq, Effexor, and Xyntha new drug registrations in China and Japan. Dr. Yan holds a doctorate in clinical medicine from Shanghai JiaoTong University Medical School/Ruijin Hospital and conducted his post-doc fellowship at Johns Hopkins University School of Medicine and Eastern Virginia Medical School.
Edward Lang Jr.
Chief Business Officer
Ed brings more than 20 years of experience in the biotechnology industry and as Chief Business Officer oversees business development, communications and investor relations. He is also building AnHeart’s initial commercial capabilities. Ed has a deep knowledge of corporate strategy, a proven track record of raising capital, and extensive experience in launching cancer medicines.
Prior to joining AnHeart, Ed served as Chief Business Officer at Gyroscope Therapeutics, a global clinical-stage gene therapy company focused on eye disease, acquired by Novartis. Ed previously served as Vice President, Corporate Affairs at Juno Therapeutics, acquired by Celgene. Prior to Juno he spent 13 years at Genentech supporting the approval and launch of 15 new medicines.
Anhu (Andrew) Li, Ph.D.
Chief Scientific Officer & Head of CMC
Dr. Anhu (Andrew) Li is Chief Scientific Officer & Head of CMC at AnHeart Therapeutics. He is a seasoned industry veteran with more than 20 years of experience in drug discovery and development, and a strong passion for improving the lives of patients worldwide.
During his career, Dr. Li has co-invented more than a dozen IND-track candidates in oncology, the majority of which were invented under his direction.
Prior to AnHeart, Dr. Li held positions as a founding member of a biotech startup and consulted for four biotech companies. Dr. Li started his industry career in 2001 at OSI Pharmaceuticals/Astellas Pharma, with increasing responsibility in discovery project leadership and CRO management.
Dr. Li holds a Ph.D. in organic chemistry from Shanghai Institute of Organic Chemistry, CAS, and received post-doctoral training at the National Institutes of Health and Harvard University. He has published over 40 peer-reviewed journal articles and co-invented over 40 PCT patent families.
Shuanglian Lian Li, M.D., Ph.D.
Senior Vice President & Chief Medical Officer (U.S.)
Dr. Shuanglian (Lian) Li is Senior Vice President & Chief Medical Officer (U.S.) at AnHeart Therapeutics. In this role, Dr. Li will oversee and direct all U.S.-based clinical programs. Dr. Li is an accomplished clinical development physician with over 15 years of drug development experience from preclinical drug safety to late-stage drug development and post-marketing clinical research. Her clinical development expertise has specialized in precision medicine and adoptive cellular therapy.
Prior to joining AnHeart, Dr. Li was SVP, Clinical Development at Ansun Biopharma, where she led and drove the overall clinical development strategy of the company’s oncology pipeline and clinical development plan. She also led clinical and regulatory strategy as Head of Clinical Development at Skyline Therapeutics, a gene therapy company headquartered in Shanghai.
Dr. Li was also the Global Clinical Lead for mobocertinib, a first-in-class EGFR inhibitor that targeted EGFR exon 20 insertions, at Takeda Pharmaceuticals. Prior to its acquisition by Takeda, Dr. Li was Medical Director at ARIAD Pharmaceuticals and the medical lead for several oncology programs. Dr. Li has held various positions with increasing responsibilities at Biogen, Pfizer and Sugen.
Dr. Li received her Ph.D. in Pharmaceutical Sciences & Pharmacogenomics, from the University of California, San Francisco and an M.D. from Beijing Medical University. She also obtained an M.S. in Pharmacology & Toxicology from the University of Mississippi.
Charlotte Arnold
Chief Corporate Affairs Officer
Charlotte is a seasoned corporate affairs executive with more than 25 years of experience in the healthcare industry, including biotech, pharma, and diagnostics. Most recently, Charlotte served as an executive at early-stage companies, where she played an integral role in setting and executing against corporate strategy, raising capital, developing corporate narrative and shaping company culture. She has built and led multiple corporate affairs functions, overseeing communications and investor relations, for both public and private companies.
Prior to joining AnHeart, Charlotte served as Senior Vice President, Corporate Affairs at Gyroscope Therapeutics, a global clinical-stage gene therapy company focused on eye disease, acquired by Novartis. She also previously served as Vice President, Corporate Affairs at GRAIL, Inc., acquired by Illumina, and Vice President, Corporate Communications and Investor Relations at Relypsa, Inc., acquired by Vifor Pharma. Prior to that she held several senior communications roles at Genentech over the span of almost 10 years.
Charlotte is a member of the Senior Advisory Board of the SF Bay Area Chapter of the Healthcare Businesswomen’s Association (HBA).
Fan Frank Fan, M.D., MBA
Senior Vice President & Head of Clinical Development Strategy
Dr. Frank Fan is Senior Vice President & Head of Clinical Development Strategy at AnHeart Therapeutics. He has nearly 25 years of working experience in clinical research and medical science functions for some global biopharmaceutical companies. Prior to joining AnHeart, Dr. Fan was the head of the medical and scientific service group, IQVIA Greater China. Dr. Fan has a Bachelor of Medicine degree from Capital Medical University and an MBA from Cranfield University.
Qinying Zhao, Ph.D.
Senior Vice President, Head of Global Clinical Pharmacology
Dr. Qinying Zhao is Senior Vice President and Head of Global Clinical Pharmacology at AnHeart Therapeutics. She has demonstrated strong leadership and decades of scientific expertise in global clinical pharmacology and clinical development. Dr. Zhao has extensive experience in clinical pharmacology strategy/execution and clinical development of innovative drugs, IND/NDA submissions, and interactions with global major regulatory agencies. Prior to AnHeart, she had worked as Global Clinical Pharmacology Lead at Janssen, Johnson & Johnson, and Pfizer. She had also served as a clinical pharmacology expert at Pfizer for maintenance and defense of marketed drugs in cardiovascular, pain, and inflammatory therapeutic areas. Dr. Zhao graduated from Fudan University. She earned her M. S. from China State Institute of Pharmaceutical Industry and Ph.D. from West Virginia University. She was a Postdoctoral Fellow at the University of Pennsylvania.
Hua Zheng, M.D., Ph.D.
Senior Vice President & Head of Global Regulatory Affairs
Dr. Hua Zheng is Senior Vice President & Head of Global Regulatory Affairs at AnHeart Therapeutics. He has more than 25 years of experience in regulatory strategy to advance global product development and registration. He has served in executive regulatory positions in a number of leadership roles (Vice President, Global Franchise Regulatory Lead, China Lead), and has held various positions at mulit-national companies such as Pfizer, J&J, Celgene, Amgen and biotech companies Advaxis and Sorrento. He has also served at the U.S. FDA. He has led and directed regulatory activities across all phases of global drug development, including US, China, Europe and Asia Pacific, in gaining approvals. Notably he served in critical leadership roles leading to market registrations for Yondelis®, Edurant®, Revlimid®, and Vidaza® in different countries with diverse regulatory challenges. Dr. Zheng holds a Ph.D. in Toxicology from University of California, Irvine. He has an M.Sc. in Pathology and completed his medical training from the former Beijing Medical University. He conducted postdoctoral research at National Cancer Institute, Kansas University Medical Center and University of California, San Diego.
Guilin Huang
Senior Vice President, Development
Guilin Huang is Senior Vice President, Development at AnHeart Therapeutics. She has more than 20 years of experience in global drug development with a focus on oncology and rare diseases, from pre-investigational new drug activities through regulatory reviews and commercialization.
Guilin joined AnHeart from Relay Therapeutics, where she served as Vice President and Head of Regulatory Affairs. Prior to Relay, she accumulated and enriched her drug development expertise as an accomplished regulatory strategist at Takeda Pharmaceuticals, ARIAD Pharmaceuticals, Chugai Pharmaceutical Co., and Vertex Pharmaceuticals.
Guilin holds a B.S. in pharmacy and Japanese from Shenyang Pharmaceutical University and earned her MBA in health sector management from Boston University. She also completed the Women Unlimited LEAD Program, a leadership development course for rising business leaders.
Michael J. Humphries, Ph.D.
Vice President, Head of U.S. Medical Affairs
Dr. Michael (Mike) Humphries is Vice President, Head of U.S. Medical Affairs at AnHeart Therapeutics. He has more than 15 years of experience in drug discovery, early development, and medical affairs. Prior to AnHeart, Mike served as Head of Lung Cancer – Global Medical Affairs at Takeda. In this role, he led Takeda’s lung franchise for global medical affairs, leading the design and implementation of the medical strategy, and KOL engagement and evidence generation plans. Prior to Takeda, he held several medical affairs and drug discovery roles at Array Biopharma, Bayer, and ARIAD Pharmaceuticals.
Mike earned his bachelor's degree in Biology from Western Colorado University and his Ph.D. in Cell and Developmental Biology from the University of Colorado at Denver.
Amy Muse
Vice President, U.S. Commercial
Amy Muse is Vice President, U.S. Commercial at AnHeart Therapeutics. Amy is an accomplished commercial leader with more than 20 years of commercial experience in the pharmaceutical and biotech industry.
Prior to AnHeart, Amy served as Vice President, Marketing at Seres Therapeutics where she led the launch of the first FDA-approved oral microbiome therapeutic. Previously, she served as the U.S. Oncology Lung Cancer Franchise lead at Takeda where she led commercial efforts for Takeda’s precision therapies for EGFR-positive and ALK-positive non-small cell lung cancer in the United States. Prior to Takeda, Amy held several commercial roles, including marketing and sales positions, at Shire, Forest Laboratories, and Merck and Co.
Amy earned her bachelor’s degree in accounting from Ohio University and an MBA in marketing from the NYU Stern School of Business.
Partners
